

# Medicines and Medical Devices Bill

---

MARSHALLED  
LIST OF AMENDMENTS  
TO BE MOVED  
IN GRAND COMMITTEE

---

[Amendments marked ★ are new or have been altered]

Amendment  
No.

Clause 1

BARONESS THORNTON  
LORD HUNT OF KINGS HEATH

- 1 Page 1, line 6, at end insert “for a period of three years beginning with the day on which this Act is passed.”

*Member’s explanatory statement*

*This amendment provides a sunset provision for Part 1 of the Bill requiring the Government to return with primary legislation.*

LORD BETHELL

- 2 Page 1, line 6, at end insert –  
“(1A) The appropriate authority may only make regulations under subsection (1) if satisfied that they would promote the health and safety of the public.”

*Member’s explanatory statement*

*This amendment provides that the appropriate authority may only make regulations under subsection (1) of Clause 1 if satisfied that they would promote the health and safety of the public.*

BARONESS THORNTON  
LORD HUNT OF KINGS HEATH  
BARONESS FINLAY OF LLANDAFF

- 3 Page 1, line 6, at end insert –  
“( ) In making regulations under subsection (1), the appropriate authority must have regard to the desirability of –  
(a) regulatory alignment with the European Medicines Agency’s medicines regulation;  
(b) regulatory alignment with EU clinical trials regulations;

**Clause 1 - continued**

- (c) recognition of and participation in the European Medicines Agency's medicines licensing processes."

**Member's explanatory statement**

*This amendment requires the appropriate authority to have regard to the desirability of regulatory alignment with EU regulations.*

BARONESS THORNTON  
LORD HUNT OF KINGS HEATH

4 Page 1, line 6, at end insert –

- “( ) The power under subsection (1) may not be exercised to –
- (a) create a criminal offence of failing to comply with a provision made in regulations; or
  - (b) modify penalties for existing criminal offences.”

**Member's explanatory statement**

*This probing amendment would remove provisions for criminal offences to be created by delegated legislation. The DPRRC considered this an inappropriate delegation of power.*

LORD LANSLEY  
LORD WOOLF  
BARONESS JOLLY

5★ Page 1, line 6, at end insert –

- “( ) In making regulations under subsection (1), the appropriate authority must have the objective of safeguarding public health by promoting the availability and supply of human medicines.”

**Member's explanatory statement**

*This amendment sets out the principal purpose for which regulations under subsection (1) should be made. The purpose reflects the “safeguarding public health” objective as contained in EU Regulations and incorporates the need for the availability and supply of medicines which are safe and effective.*

LORD SHARKEY  
LORD FORSYTH OF DRUMLEAN  
LORD JUDGE  
BARONESS ANDREWS

6 Page 1, line 6, at end insert –

- “( ) Regulations made under subsection (1) are subject, in relation to regulations made by the Secretary of State, to the super-affirmative procedure set out in section (*Super-affirmative procedure*), in relation to regulations made by a Northern Ireland department, to section (*Super-affirmative procedure: Northern Ireland*), and, in relation to regulations of the Secretary of State and a Northern Ireland department acting jointly, to both.”

**Member's explanatory statement**

*This amendment, and the amendments to page 5 line 12, page 7 line 22 and page 9 line 27 in the name of Lord Sharkey, replace the existing affirmative procedure with a super-affirmative procedure in order to increase parliamentary scrutiny.*

LORD BETHELL

- 7 Page 1, line 7, leave out “making regulations under subsection (1)” and insert “considering whether they would”

**Member's explanatory statement**

*This amendment requires the appropriate authority to have regard to the factors mentioned in subsection (2)(a), (b) and (c) of Clause 1 in considering whether regulations made under subsection (1) would promote the health and safety of the public.*

BARONESS THORNTON  
LORD HUNT OF KINGS HEATH

- 8 Page 1, line 8, leave out “have regard to” and insert “act with a view to ensuring”

**Member's explanatory statement**

*This amendment places a duty on the Secretary of State to act with a view to ensuring, rather than have regard to, safety, availability and UK attractiveness when exercising powers.*

LORD SHARKEY  
BARONESS JOLLY

- 9 Page 1, line 8, at end insert “, and, in the case of regulations not subject to section 42(6), (7) or (8), must publish with the draft regulations an assessment of their impact on,”

BARONESS CUMBERLEGE  
BARONESS BURT OF SOLIHULL  
BARONESS HOLLINS  
LORD PATEL

- 10 Page 1, line 8, at end insert “the safety of human medicines as the overriding consideration.”

LORD LANSLEY  
LORD WOOLF  
BARONESS JOLLY

- 11 Page 1, line 9, leave out paragraphs (a) and (b)

**Member's explanatory statement**

*This amendment is linked to the amendment in the name of Lord Lansley to page 1, line 6, which creates the objectives of the regulation; it leaves out those aspects which are included and strengthened in the objectives in the related amendment.*

BARONESS CUMBERLEGE  
 BARONESS BURT OF SOLIHULL  
 BARONESS HOLLINS  
 LORD PATEL

- 12 Page 1, line 9, leave out paragraph (a) and insert –  
 “() In making regulations under subsection (1), the appropriate authority must also have regard to the following as secondary considerations –”

LORD SHARKEY  
 BARONESS JOLLY

- 13 Page 1, line 9, at beginning insert “the priority of ensuring”

LORD BETHELL

- 14 Page 1, line 11, leave out paragraph (c) and insert –  
 “(c) the likelihood of the relevant part of the United Kingdom being seen as an attractive or favourable place in which to conduct clinical trials or supply human medicines.”

***Member’s explanatory statement***

*This amendment clarifies what was meant by the version of Clause 1(2)(c) in the Bill as brought from the House of Commons.*

LORD SHARKEY  
 BARONESS JOLLY  
 BARONESS FINLAY OF LLANDAFF

- 15 Page 1, line 11, leave out paragraph (c) and insert –  
 “(c) maintaining or improving the attractiveness of the relevant part of the United Kingdom as a place in which to conduct clinical trials or supply or manufacture human medicines”

LORD LANSLEY  
 LORD WOOLF

- 16 Page 1, line 12, after “trials” insert “, promote medical innovation”

***Member’s explanatory statement***

*This amendment broadens the aspect to which the appropriate authority must have regard from clinical trials to include promoting medical innovation.*

- 17 Page 1, line 12, at end insert –  
 “() the effect of the regulations on the ability of the National Health Service to meet the needs of patients;  
 () the result of any consultation under section 41.”

***Member’s explanatory statement***

*This amendment adds further aspects to which the appropriate authority must have regard in making regulations under section 1(1), to include the impact on the NHS and the results of consultation undertaken in accordance with section 41.*

## BARONESS BENNETT OF MANOR CASTLE

18 Page 1, line 12, at end insert –

“(d) the environmental and social impact of such medicines, including their manufacturing.”

***Member’s explanatory statement***

*This amendment seeks to ensure that the environmental and social impact of medicines is considered in the making of regulations.*

## BARONESS SHEEHAN

## BARONESS JOLLY

19★ Page 1, line 12, at end insert –

“(d) citizens’ right to access medicines as part of the right to the highest attainable standard of physical and mental health as stated in the International Covenant on Economic, Social and Cultural Rights of 1966;

(e) the public health safeguards within the World Trade Organization’s Agreement on Trade-Related Aspects of Intellectual Property Rights (“TRIPS Agreement”) which include but are not limited to –

- (i) the right to grant compulsory licences and the freedom to determine the grounds upon which licences are granted;
- (ii) the right to determine what constitutes a national emergency and circumstances of extreme urgency;
- (iii) the freedom to establish the regime of exhaustion of intellectual property rights.”

## BARONESS THORNTON

## LORD HUNT OF KINGS HEATH

## BARONESS WATKINS OF TAVISTOCK

## LORD PATEL

20 Page 1, line 12, at end insert –

“( ) In subsection (2), “attractiveness” means –

- (a) suitability for facilitating the supply and demand of medicinal products or related services;
- (b) favourability to the establishment of research, design or manufacture of medicinal products or related services; and
- (c) favourability to facilitating prompt access to new medicines once they have been approved.

( ) In making regulations under subsection (1), subsection (2)(a) relating to the safety of human medicines must be prioritised above subsection (2)(b) relating to the availability of human medicines and subsection (2)(c) relating to attractiveness.”

***Member’s explanatory statement***

*This amendment provides a definition of attractiveness for clarity, and clarifies the primacy of safety.*

LORD PATEL  
LORD MACKAY OF CLASHFERN

21 Page 1, line 12, at end insert –

- “( ) In subsection (2)(c), “attractiveness” means the quality of being –
- (a) suitable to facilitate the supply and demand of medicinal products or related services; or
  - (b) favourable to the establishment of research, design or manufacture of medicinal products or related services.
- ( ) In regulations under subsection (1), subsection (2)(a) must be prioritised above subsection (2)(b) and (2)(c).”

***Member’s explanatory statement***

*This amendment ensures that patient safety remains a priority.*

LORD HUNT OF KINGS HEATH  
BARONESS FINLAY OF LLANDAFF

22 Page 1, line 12, at end insert –

- “( ) In subsection (2)(c), “attractiveness” means favourability for –
- (a) the conduct of clinical trials of and research into new medicines, including for rare diseases;
  - (b) establishing expertise and forging international regulatory standards in areas of strategic importance to the United Kingdom, including cell and gene therapy;
  - (c) collaborating with the European Medicines Agency and other international regulators;
  - (d) conducting discussions regarding reimbursement in parallel with the process of granting marketing authorisations for new medicines; or
  - (e) facilitating prompt access to new medicines once they have been approved through the implementation of new approaches to reimbursement.”

***Member’s explanatory statement***

*This amendment provides a definition of attractiveness for clarity.*

**Clause 2**

BARONESS THORNTON  
LORD HUNT OF KINGS HEATH

23 Page 2, line 8, leave out paragraph (c)

***Member’s explanatory statement***

*This is a probing amendment that would omit the Secretary of State’s power to make changes to wholesale dealing, including hub and spoke models.*

LORD HUNT OF KINGS HEATH  
BARONESS FINLAY OF LLANDAFF  
BARONESS NORTHOVER  
LORD RIBEIRO

24 Page 2, line 23, at end insert –

“(o) the origin and treatment of human tissue used in the process of developing and manufacturing medicines.”

***Member’s explanatory statement***

*This amendment adds the origin and treatment of human tissue, including organs, to the list of matters about which regulations may be made by the appropriate authority, in the context that informed, valid, uncoerced and demonstrably documented consent may not have been given for the harvesting of such human tissue and organs.*

BARONESS BENNETT OF MANOR CASTLE

25 Page 2, line 23, at end insert –

“(o) the disposal of unused or waste medicines and the impact of medicines, or their derivatives, entering the environment.”

***Member’s explanatory statement***

*This amendment seeks to ensure that the regulations can make provision about the disposal of medicines.*

BARONESS FINLAY OF LLANDAFF  
LORD HUNT OF KINGS HEATH

26 Page 2, line 23, at end insert –

“(o) developing rapid provisional two-year licences.”

LORD PATEL  
LORD HUNT OF KINGS HEATH

27 Page 2, line 35, at end insert –

“( ) Regulations under section 1(1) must make provision to enable the Medicines and Healthcare products Regulatory Agency to work with other regulators to minimise delay for the United Kingdom to get early access to new medicines.”

**After Clause 2**

LORD LANSLEY  
LORD WOOLF  
LORD PATEL

28 Insert the following new Clause –

**“Innovative Medicines Fund**

In section 261 of the National Health Service Act 2006, after subsection (9) insert –

“(9A) The Secretary of State must make a scheme to promote the availability of innovative medicines for human use within the National Health Service and must provide monies paid to him or her under subsection (9) for the benefit of that scheme to be known as the “Innovative Medicines Fund”.”

**Member's explanatory statement**

*This amendment would require the Secretary of State to establish the Innovative Medicines Fund, as foreshadowed in the Conservative 2019 Manifesto; and provides that it is funded from rebates paid to the Government under the terms of the Pharmaceutical Price Regulation Scheme.*

LORD CLEMENT-JONES  
LORD HUNT OF KINGS HEATH

29 Insert the following new Clause –

**“Hub and spoke framework**

- (1) Within six months of the day on which this Act is passed, the Secretary of State must –
  - (a) consult the pharmaceutical wholesale and pharmacy sectors and their regulators on an agreed framework for the safe transfer of patient data, prescription information and dispensed products between separate legal entities when operating any form of third-party hub and spoke dispensing model; and
  - (b) lay a copy of the agreed framework before Parliament.
- (2) The Secretary of State must have regard to the agreed framework when making regulations under section 1(1).”

**Member's explanatory statement**

*This new Clause is intended to ensure the government consults with stakeholders on how hub and spoke is used and agrees a framework with the support of the relevant sectors. This will ensure that the expected savings and efficiencies, and new healthcare services via pharmacies, can be achieved.*

**Clause 3**

BARONESS THORNTON  
LORD CLEMENT-JONES  
LORD HUNT OF KINGS HEATH

30 Page 2, line 39, leave out “, for any purpose to do with human medicines,”

**Member's explanatory statement**

*This amendment tightens the provisions to avoid unintended consequences of data being used for purposes other than to ensure that medicines are safe.*

LORD CLEMENT-JONES

31 Page 2, line 41, at end insert “subject to subsection (1A)”

**Member's explanatory statement**

*This amendment is a paving amendment for the amendment also in the name of Lord Clement-Jones to page 2, line 41.*

LORD CLEMENT-JONES  
LORD HUNT OF KINGS HEATH

32 Page 2, line 41, at end insert –

“(1A) Within 6 months of this Act coming into force, the Secretary of State must –



**Clause 3 - continued**

- (a) consult with the pharmaceutical and pharmacy community on an agreed framework outlining the use, retention and disclosure of information collected for the purpose of preventing the supply of falsified human medicines; and
- (b) lay a copy of the agreed framework before Parliament.”

***Member’s explanatory statement***

*This amendment seeks to avoid unintended consequences as a result of data being used for purposes other than to ensure that medicines are safe, and therefore would require a framework for data use to be agreed in consultation with the pharmaceutical industry.*

BARONESS THORNTON

- 33 Page 3, line 12, leave out “have regard to the importance of” and insert “act with a view to”

***Member’s explanatory statement***

*This amendment places a duty on the Secretary of State to act with a view to, rather than have regard to the importance of, ensuring that information is retained securely when exercising powers.*

**Clause 4**LORD SHARKEY  
BARONESS JOLLY

- 34 Page 3, line 15, leave out “may” and insert “must”

LORD LANSLEY  
LORD KAKKAR

- 35 Page 3, line 16, leave out “or similar”

***Member’s explanatory statement***

*This amendment leaves out “or similar” in the description of the power to make clinical trials regulations. It would have the effect that regulations should correspond to the EU Clinical Trials Regulation. It seeks to establish whether, and to what extent, Ministers intend to depart from the EU Regulation.*

LORD SHARKEY  
BARONESS JOLLY

- 36 Page 3, line 16, after “similar” insert “, where possible,”

- 37 Page 3, line 17, at end insert “including the revised definitions of “clinical trial” and “co-sponsorship””

**Clause 4 - continued**

BARONESS THORNTON  
LORD PATEL  
LORD HUNT OF KINGS HEATH  
LORD MACKAY OF CLASHFERN

38 Page 3, line 25, at end insert –

“(f) to support the involvement of the United Kingdom in EU-wide clinical trials.”

***Member’s explanatory statement***

*This amendment allows the Secretary of State to make regulations to continue the UK’s collaboration with clinical trials involving multiple EU countries.*

LORD PATEL  
LORD HUNT OF KINGS HEATH

39 Page 3, line 25, at end insert –

“(f) to develop a clinical trials portal that aligns with the European Medicines Agency for medicines for rare diseases.”

LORD PATEL

40★ Page 3, line 25, at end insert –

“(f) about requirements to consider babies, children and young people in research about new medicines, in a manner similar to the EU Paediatric Regulation.”

***Member’s explanatory statement***

*This amendment is to ensure that in the development of new medicines and clinical trials, data related to children is taken into consideration.*

BARONESS BENNETT OF MANOR CASTLE

41★ Page 3, line 25, at end insert –

“( ) Regulations must be made under section 1(1) to require reporting on antimicrobial resistance in the microbiota of subjects during receipt of the drug in clinical trials and during the follow-up period.”

**Clause 5**

BARONESS THORNTON  
LORD PATEL  
LORD PANNICK  
LORD MACKAY OF CLASHFERN

42 Page 3, line 34, leave out paragraph (b)

***Member’s explanatory statement***

*This probing amendment would remove provisions for criminal offences to be created by delegated legislation.*

## LORD BETHELL

43 Page 3, line 35, leave out from “regulations,” to “or” in line 36

***Member’s explanatory statement***

*See the explanatory statement for the amendment in the Minister’s name inserting new subsection (1A) into Clause 5.*

44 Page 3, line 39, at end insert –

“(1A) Regulations under section 1(1) may not provide for an offence to be punishable with a sentence of imprisonment of more than two years.”

***Member’s explanatory statement***

*This amendment, and the other amendment to Clause 5 in the Minister’s name, ensures that regulations under Clause 1(1) may not provide for any offence to be punishable with a sentence of imprisonment of more than two years.*

## BARONESS THORNTON

45 Page 3, line 39, at end insert –

“(1A) The Secretary of State must publish a fees regime in relation to subsection (1)(a) within three months of the date on which this Act is passed.”

***Member’s explanatory statement***

*This amendment requires the Secretary of State to publish their proposed list of fees in respect of human medicines.*

**Clause 6**

BARONESS THORNTON  
LORD HUNT OF KINGS HEATH  
LORD PATEL

46 Page 4, line 12, leave out paragraph (b)

***Member’s explanatory statement***

*This amendment removes provision for the disapplication of regulatory provisions in an emergency to be made subject to conditions set out in a protocol published by ministers, which is not subject to parliamentary scrutiny.*

BARONESS THORNTON  
LORD PATEL

47 Page 4, line 13, leave out subsection (3)

***Member’s explanatory statement***

*This amendment removes provision for the disapplication of regulatory provisions in an emergency to be made subject to conditions set out in a protocol published by ministers, which is not subject to parliamentary scrutiny.*

### After Clause 6

LORD BETHELL

48 Insert the following new Clause—

**“Disclosure of information in accordance with international agreements**

- (1) This section applies to information which a relevant authority holds in connection with human medicines.
- (2) The relevant authority may disclose information to a person outside the United Kingdom where required for the purpose of giving effect to an international agreement or arrangement concerning the regulation of human medicines.
- (3) The relevant authority may not disclose commercially sensitive information in reliance on subsection (2) unless the relevant authority—
  - (a) considers that it is necessary to do so for the purpose mentioned in that subsection, and
  - (b) is satisfied that the making of the disclosure is proportionate to what is sought to be achieved by it.
- (4) Except as provided by subsection (5), the disclosure of information in accordance with this section does not breach—
  - (a) an obligation of confidence owed by the person making the disclosure, or
  - (b) any other restriction on the disclosure of the information (however imposed).
- (5) Nothing in this section authorises a disclosure of information which—
  - (a) contravenes the data protection legislation (but in determining whether a disclosure would do so, take into account the powers conferred by this section), or
  - (b) is prohibited by any of Parts 1 to 7 or Chapter 1 of Part 9 of the Investigatory Powers Act 2016.
- (6) In this section—
 

“commercially sensitive information” means commercial information whose disclosure the relevant authority thinks might significantly harm the legitimate business interests of the undertaking to which it relates;

“relevant authority” means—

  - (a) the Secretary of State, or
  - (b) the Department of Health in Northern Ireland;

“data protection legislation” has the meaning given by section 3(9) of the Data Protection Act 2018.”

***Member’s explanatory statement***

*This new Clause makes clear that information held by the Secretary of State or the Department of Health in Northern Ireland in connection with human medicines can be disclosed, subject to certain restrictions, to persons outside the United Kingdom in order to give effect to a relevant international agreement or arrangement.*

BARONESS THORNTON  
LORD HUNT OF KINGS HEATH  
LORD RAMSBOTHAM  
LORD BRADLEY

49 Insert the following new Clause—

**“Extending prescribing rights**

The Secretary of State must, within three months of this Act being passed, lay before each House of Parliament proposals and a timetable for extending prescribing rights to additional healthcare professionals under section 2(1)(n).”

*Member’s explanatory statement*

*This new Clause requires the Secretary of State to publish proposals and a timetable for additional healthcare professionals to be given appropriately restricted prescribing rights.*

LORD PATEL  
LORD KAKKAR

50 Insert the following new Clause—

**“Requirement for consolidated legislation: human medicines**

The Secretary of State must publish draft legislation consolidating existing legislation as it applies to human medicines within three years after the day on which this Act is passed.”

*Member’s explanatory statement*

*This new Clause would commit the Secretary of State to introducing new, streamlined legislation within three years.*

**Clause 8**

LORD BETHELL

51 Page 5, line 12, at end insert—

“(1A) The appropriate authority may only make regulations under subsection (1) if satisfied that they would promote one or more of the following—

- (a) the health and welfare of animals;
- (b) the health and safety of the public;
- (c) the protection of the environment.”

*Member’s explanatory statement*

*This amendment provides that the appropriate authority may only make regulations under subsection (1) of Clause 8 if satisfied that they would promote the health or welfare of animals, the health and safety of the public or the protection of the environment.*

BARONESS THORNTON  
LORD HUNT OF KINGS HEATH

52 Page 5, line 12, at end insert—

“(1A) The power under subsection (1) may not be exercised to—

- (a) create a criminal offence of failing to comply with a provision made in regulations; or
- (b) modify penalties for existing criminal offences.”

**Member's explanatory statement**

*This probing amendment would remove provisions for criminal offences to be created by delegated legislation.*

LORD SHARKEY  
LORD JUDGE

53 Page 5, line 12, at end insert –

“(1A) Regulations made under subsection (1) are subject, in relation to regulations made by the Secretary of State, to the super-affirmative procedure set out in section (*Super-affirmative procedure*), in relation to regulations made by a Northern Ireland department, to section (*Super-affirmative procedure: Northern Ireland*), and, in relation to regulations of the Secretary of State and a Northern Ireland department acting jointly, to both.”

**Member's explanatory statement**

*This amendment, and the amendments to page 1 line 6, page 7 line 22 and page 9 line 27 in the name of Lord Sharkey, replace the existing affirmative procedure with a super-affirmative procedure in order to increase parliamentary scrutiny.*

LORD BETHELL

54 Page 5, line 13, leave out “making regulations under subsection (1)” and insert “considering whether they would”

**Member's explanatory statement**

*This amendment requires the appropriate authority to have regard to the factors mentioned in subsection (2)(a), (b) and (c) of Clause 8 in considering whether regulations under subsection (1) would promote the health or welfare of animals, the health and safety of the public or the protection of the environment.*

BARONESS THORNTON

55 Page 5, line 14, leave out “have regard to” and insert “act with a view to ensuring”

**Member's explanatory statement**

*This amendment places a duty on the Secretary of State to act with a view to ensuring, rather than have regard to, safety, availability and UK attractiveness when exercising powers.*

LORD BETHELL

56 Page 5, line 15, leave out “in relation to animals, humans and the environment”

**Member's explanatory statement**

*This amendment is consequential on the amendment in the Minister's name inserting a new subsection after subsection (1) of Clause 8.*

57 Page 5, line 18, leave out paragraph (c) and insert –

“(c) the likelihood of the relevant part of the United Kingdom being seen as an attractive or favourable place in which to develop or supply veterinary medicines.”

**Member's explanatory statement**

*This amendment clarifies what was meant by the version of Clause 8(2)(c) in the Bill as brought from the House of Commons.*

LORD SHARKEY  
BARONESS JOLLY

- 58 Page 5, line 18, leave out paragraph (c) and insert –
- “(c) maintaining or improving the attractiveness of the relevant part of the United Kingdom as a place in which to conduct clinical trials or supply or manufacture veterinary medicines.”

BARONESS BENNETT OF MANOR CASTLE

- 59 Page 5, line 19, at end insert –
- “(d) the welfare of animals which will be treated by veterinary medicines.”

**Member's explanatory statement**

*This amendment seeks to ensure that animal welfare is considered in the making of regulations.*

BARONESS THORNTON

- 60 Page 5, line 19, at end insert –
- “(2A) In subsection (2), “attractiveness” means –
- (a) suitability for facilitating the supply and demand of veterinary medicinal products or related services;
  - (b) favourability to the establishment of research, design, or manufacture of veterinary medicinal products or related services; and
  - (c) favourability to facilitating prompt access to new veterinary medicines once they have been approved.
- (2B) In making regulations under subsection (1), subsection (2)(a) relating to the safety of veterinary medicines must be prioritised above subsection (2)(b) relating to the availability of veterinary medicines and subsection (2)(c) relating to attractiveness.”

**Member's explanatory statement**

*This amendment provides a definition of attractiveness for clarity, and clarifies the primacy of safety.*

LORD PATEL  
LORD MACKAY OF CLASHFERN

- 61 Page 5, line 19, at end insert –
- “( ) In subsection (2)(c), “attractiveness” means the quality of being –
- (a) suitable to facilitate the supply and demand of veterinary medicinal products or related services; or
  - (b) favourable to the establishment of research, design or manufacture of veterinary medicinal products or related services.
- ( ) In regulations under subsection (1), subsection (2)(a) must be prioritised above subsection (2)(b) and (2)(c).”

**Member's explanatory statement**

*This amendment ensures that safety remains a priority.*

**Clause 9**

BARONESS THORNTON

62 Page 6, line 11, at end insert –

“(1A) The Secretary of State must by regulations make provision about the use of the Cascade.”

**Member's explanatory statement**

*This amendment gives the Secretary of State the responsibility to make provisions regarding the Cascade, a risk-based decision process where veterinarians can dispense different medicines to animals beyond the terms of authorisation.*

**Clause 10**

BARONESS THORNTON

LORD PATEL

LORD PANNICK

LORD MACKAY OF CLASHFERN

63 Page 6, line 26, leave out paragraph (b)

**Member's explanatory statement**

*This probing amendment would remove provisions for criminal offences to be created by delegated legislation.*

LORD BETHELL

64 Page 6, line 27, leave out from “regulations,” to end of line 28

**Member's explanatory statement**

*See the explanatory statement for the amendment in the Minister's name inserting new subsection (1A) into Clause 10.*

65 Page 6, line 35, at end insert –

“(1A) Regulations under section 8(1) may not provide for an offence to be punishable with a sentence of imprisonment of more than two years.”

**Member's explanatory statement**

*This amendment, and the other amendment to clause 10 in the Minister's name, ensures that regulations under Clause 8(1) may not provide for any offence to be punishable with a sentence of imprisonment of more than two years.*



### After Clause 10

LORD BETHELL

66 Insert the following new Clause—

**“Disclosure of information in accordance with international agreements**

- (1) This section applies to information which a relevant authority holds in connection with veterinary medicines.
- (2) The relevant authority may disclose information to a person outside the United Kingdom where required for the purpose of giving effect to an international agreement or arrangement concerning the regulation of veterinary medicines.
- (3) The relevant authority may not disclose commercially sensitive information in reliance on subsection (2) unless the relevant authority—
  - (a) considers that it is necessary to do so for the purpose mentioned in that subsection, and
  - (b) is satisfied that the making of the disclosure is proportionate to what is sought to be achieved by it.
- (4) Except as provided by subsection (5), the disclosure of information in accordance with this section does not breach—
  - (a) an obligation of confidence owed by the person making the disclosure, or
  - (b) any other restriction on the disclosure of the information (however imposed).
- (5) Nothing in this section authorises a disclosure of information which—
  - (a) contravenes the data protection legislation (but in determining whether a disclosure would do so, take into account the powers conferred by this section), or
  - (b) is prohibited by any of Parts 1 to 7 or Chapter 1 of Part 9 of the Investigatory Powers Act 2016.
- (6) In this section—
 

“commercially sensitive information” means commercial information whose disclosure the relevant authority thinks might significantly harm the legitimate business interests of the undertaking to which it relates;

“relevant authority” means—

  - (a) the Secretary of State, or
  - (b) the Department of Agriculture, Environment and Rural Affairs in Northern Ireland;

“data protection legislation” has the meaning given by section 3(9) of the Data Protection Act 2018.”

***Member’s explanatory statement***

*This new Clause makes clear that information held by the Secretary of State or the Department of Agriculture, Environment and Rural Affairs in Northern Ireland in connection with veterinary medicines can be disclosed, subject to certain restrictions, to persons outside the United Kingdom in order to give effect to a relevant international agreement or arrangement.*

LORD PATEL  
LORD KAKKAR

67 Insert the following new Clause –

**“Requirement for consolidated legislation: veterinary medicines**

The Secretary of State must publish draft legislation consolidating existing legislation as it applies to veterinary medicines within three years after the day on which this Act is passed.”

***Member’s explanatory statement***

*This new Clause would commit the Secretary of State to introducing new, streamlined legislation within three years.*

**Clause 12**

LORD BETHELL

68 Page 7, line 22, at end insert –

“(1A) The Secretary of State may only make regulations under subsection (1) if satisfied that they would promote the health and safety of the public.”

***Member’s explanatory statement***

*This amendment provides that the Secretary of State may only make regulations under subsection (1) of Clause 12 if satisfied that they would promote the health and safety of the public.*

BARONESS THORNTON  
LORD HUNT OF KINGS HEATH

69 Page 7, line 22, at end insert –

“(1A) The power under subsection (1) may not be exercised to –

- (a) create a criminal offence of failing to comply with a provision made in regulations; or
- (b) modify penalties for existing criminal offences.”

***Member’s explanatory statement***

*This probing amendment would remove provisions for criminal offences to be created by delegated legislation.*

LORD LANSLEY  
LORD WOOLF

70 Page 7, line 22, at end insert –

“(1A) In making regulations under subsection (1), the Secretary of State must have the objective to safeguard public health through the supply of medical devices.”

***Member’s explanatory statement***

*This amendment would establish an objective of safeguarding public health, for which regulations relating to medical devices must be made.*

LORD SHARKEY  
LORD FORSYTH OF DRUMLEAN  
LORD JUDGE  
BARONESS ANDREWS

71 Page 7, line 22, at end insert –

“(1A) Regulations made under subsection (1) are subject, in relation to regulations made by the Secretary of State, to the super-affirmative procedure set out in section (*Super-affirmative procedure*), in relation to regulations made by a Northern Ireland department, to section (*Super-affirmative procedure: Northern Ireland*), and, in relation to regulations of the Secretary of State and a Northern Ireland department acting jointly, to both.”

***Member’s explanatory statement***

*This amendment, and the amendments to page 1, line 6, page 5 line 12 and page 9 line 27 in the name of Lord Sharkey, replace the existing affirmative procedure with a super-affirmative procedure in order to increase parliamentary scrutiny.*

LORD BETHELL

72 Page 7, line 23, leave out “making regulations under subsection (1)” and insert “considering whether they would”

***Member’s explanatory statement***

*This amendment requires the Secretary of State to have regard to the factors mentioned in subsection (2)(a), (b) and (c) of Clause 12 in considering whether regulations under subsection (1) would promote the health and safety of the public.*

BARONESS THORNTON  
LORD HUNT OF KINGS HEATH

73 Page 7, line 23, leave out “have regard to” and insert “act with a view to ensuring”

***Member’s explanatory statement***

*This amendment places a duty on the Secretary of State to act with a view to ensuring, rather than have regard to, safety, availability and UK attractiveness when exercising powers.*

BARONESS CUMBERLEGE  
BARONESS BURT OF SOLIHULL  
LORD PATEL  
LORD HUNT OF KINGS HEATH

74 Page 7, line 24, at end insert “the safety of medical devices as the overriding consideration.”

75 Page 7, leave out line 25 and insert –

“( ) In making regulations under subsection (1), the appropriate authority must also have regard to the following as secondary considerations – ”

LORD LANSLEY  
LORD WOOLF

76 Page 7, line 25, at end insert “including in therapeutic practice”

**Member's explanatory statement**

*This amendment would require the Secretary of State to have regard to the safety of medical devices in the context of their therapeutic use.*

LORD BETHELL

77 Page 7, line 27, leave out paragraph (c) and insert –

“(c) the likelihood of the United Kingdom being seen as an attractive or favourable place in which to develop or supply medical devices.”

**Member's explanatory statement**

*This amendment clarifies what was meant by the version of Clause 12(2)(c) in the Bill as brought from the House of Commons.*

LORD SHARKEY  
BARONESS JOLLY

78 Page 7, line 27, leave out paragraph (c) and insert –

“(c) maintaining or improving the attractiveness of the relevant part of the United Kingdom as a place in which to conduct clinical trials or supply or manufacture medical devices.”

LORD LANSLEY  
LORD WOOLF

79 Page 7, line 28, at end insert –

“(d) the effect of the regulations on the ability of the National Health Service to meet the needs of patients;  
(e) the result of any consultations under section 41.”

**Member's explanatory statement**

*This amendment would add to the matters to which the Secretary of State must have regard in making medical devices regulations, to include the impact on the NHS and the results of consultation conducted in accordance with section 41.*

BARONESS BENNETT OF MANOR CASTLE

80 Page 7, line 28, at end insert –

“(d) the environmental and social impact of medical devices.”

**Member's explanatory statement**

*This amendment seeks to ensure that the environmental and social impact of producing and disposing of devices is considered in the making of regulations.*

BARONESS THORNTON  
LORD HUNT OF KINGS HEATH

81 Page 7, line 28, at end insert –

“(3) In subsection (2), “attractiveness” means –  
(a) suitability for facilitating the supply and demand of medical devices;  
(b) favourability to the establishment of research, design or manufacture of medical devices; and  
(c) favourability to facilitating prompt access to new medical devices once they have been approved.

**Clause 12 - continued**

- (4) In making regulations under subsection (1), subsection (2)(a) relating to the safety of medical devices must be prioritised above subsection (2)(b) relating to the availability of medical devices and subsection (2)(c) relating to attractiveness.”

***Member’s explanatory statement***

*This amendment provides a definition of attractiveness for clarity, and clarifies the primacy of safety.*

LORD PATEL

LORD MACKAY OF CLASHFERN

82 Page 7, line 28, at end insert –

- “(3) In subsection (2), “attractiveness” means the quality of being –
- (a) suitable to facilitate the supply and demand of medical devices or related services; or
  - (b) favourable to the establishment of research, design or manufacture of medical devices or related services.
- (4) In making regulations under subsection (1), subsection (2)(a) must be prioritised above subsection (2)(b) and (2)(c).”

***Member’s explanatory statement***

*This amendment ensures that patient safety remains a priority.*

LORD FREYBERG

LORD CLEMENT-JONES

83 Page 7, line 28, at end insert –

- “(3) Within 12 months of this section coming into force, the Secretary of State must initiate a comprehensive technical review of the definition of “medical device” under the Medical Devices Regulations 2002 with a view to addressing the inclusion of artificial intelligence software and algorithms including methodologies for the interpretation of data and associated technical architecture in medical devices.”

***Member’s explanatory statement***

*This amendment seeks to improve how the Bill addresses new technologies which have significant potential for harm, aligning with and improving on the EU and US equivalents.*

**Clause 13**

BARONESS FINLAY OF LLANDAFF

BARONESS CUMBERLEGE

84 Page 7, line 37, at end insert –

- “(iii) requirements about notification and reporting requirements in relation to clinical investigations undertaken to assess the safety or performance of a device,”

**Member's explanatory statement**

*This amendment creates a power for the Secretary of State to make regulations about clinical investigations, using the definition presently operating in EU Regulation on Medical Devices 2017/745. The amendment allows discussion of medical device trials being registered on a publicly accessible database within six weeks, as is present practice for medicine trials.*

LORD LANSLEY

85 Page 7, line 37, at end insert –

“(aa) requirements that, in accordance with any recommendation of the National Institute for Health and Care Excellence, the National Health Service should make a medical device available for use within a specified period,”

**Member's explanatory statement**

*This amendment would provide for the Medical Devices Regulations to include a funding mandate to the NHS to make NICE-approved devices available in the NHS. This would correspond to the funding mandate applicable to NICE-approved human medicines.*

BARONESS FINLAY OF LLANDAFF

LORD RIBEIRO

86 Page 8, line 11, after “and” insert “unique device identification,”

**Member's explanatory statement**

*This amendment seeks to raise the issue of tracking of medical devices. Coupled with amendments by Baroness Finlay to page 8, line 17 and page 10, line 20, it would allow regulations to provide for the tracking of all devices via a Unique Device Identifier, as they are used, with the information recorded either in registries or through hospital episode statistics data.*

BARONESS FINLAY OF LLANDAFF

87 Page 8, line 15, after “maintaining” insert “, and ensuring expert oversight of,”

**Member's explanatory statement**

*This amendment would raise the issue of expert panels overseeing registries, able to identify the right data points and to monitor both outlier performance and broad trends from the information a registry comes to contain.*

BARONESS FINLAY OF LLANDAFF

LORD RIBEIRO

88 Page 8, line 17, leave out from first “to” to end of line 18 and insert “the use of medical devices in individual procedures to be tracked and entered in a register, or within hospital episode statistics data, and”

**Member's explanatory statement**

*This amendment seeks to raise the issue of tracking of medical devices. Coupled with amendments by Baroness Finlay to page 8, line 11 and page 10, line 20, it would allow regulations to provide for the tracking of all devices via a unique device identifier, as they are used, with the information recorded either in registries or through hospital episode statistics data.*

BARONESS THORNTON  
BARONESS WATKINS OF TAVISTOCK

89 Page 8, line 23, at end insert –

“( ) notification and reporting requirements for medical device clinical investigations.”

***Member’s explanatory statement***

*This amendment would allow the Secretary of State to make regulations about notification and reporting requirements for medical device clinical investigations, as is currently the case for medicines.*

BARONESS FINLAY OF LLANDAFF  
LORD HUNT OF KINGS HEATH

90 Page 8, line 27, at end insert –

“( ) The provision mentioned in subsection (1)(b) may include provision for the development of a rapid provisional 2-year licensing procedure.”

BARONESS BENNETT OF MANOR CASTLE

91★ Page 8, line 27, at end insert –

“( ) Regulations must be made under section 12(1) to require re-usable medical devices to be designed to facilitate decontamination, and manufacturers of re-usable medical devices to provide advice on the decontamination of their products in line with standard decontamination practice.”

**Clause 14**

LORD PANNICK  
LORD PATEL  
LORD MACKAY OF CLASHFERN  
LORD JUDGE

92 Page 8, line 41, leave out paragraph (d)

***Member’s explanatory statement***

*This amendment removes the power conferred on the Secretary of State to create criminal offences.*

**Clause 15**

BARONESS THORNTON  
LORD PATEL

93 Page 9, line 8, leave out paragraph (b)

***Member’s explanatory statement***

*This amendment removes provision for the disapplication of regulatory provisions in an emergency to be made subject to conditions set out in a protocol published by ministers, which is not subject to parliamentary scrutiny.*

94 Page 9, line 9, leave out subsection (3)

**Member's explanatory statement**

*This amendment removes provision for the disapplication of regulatory provisions in an emergency to be made subject to conditions set out in a protocol published by ministers, which is not subject to parliamentary scrutiny.*

**Clause 16**

BARONESS FINLAY OF LLANDAFF

95 Page 9, line 18, leave out “may” and insert “must”

**Member's explanatory statement**

*This amendment is designed to seek assurances from the Minister that the Government will proceed to make regulations under the Bill, setting up the new information system envisaged by Clause 16.*

BARONESS THORNTON

96 Page 9, line 22, after “of” insert “all”

**Member's explanatory statement**

*This is a probing amendment seeking clarity about whether the Government intends to track all medical devices used in the UK, rather than a selection.*

LORD KAKKAR

LORD PATEL

97 Page 9, line 27, at end insert –

“(d) provisional licences granted for new devices before they are placed on the market to inform the decision whether to grant final marketing authorisation under a full licence.”

**Member's explanatory statement**

*The purpose of this amendment is to extend the reach of Clause 16 to include provision for the establishment of an information system for assessing the safety and performance of medical devices before they are placed on the market, via a provisional licence.*

LORD SHARKEY

LORD FORSYTH OF DRUMLEAN

BARONESS ANDREWS

98 Page 9, line 27, at end insert –

“( ) Regulations made under subsection (1) are subject, in relation to regulations made by the Secretary of State, to the super-affirmative procedure set out in section (*Super-affirmative procedure*), in relation to regulations made by a Northern Ireland department, to section (*Super-affirmative procedure: Northern Ireland*), and, in relation to regulations of the Secretary of State and a Northern Ireland department acting jointly, to both.”

**Member's explanatory statement**

*This amendment, and the amendments to page 1, line 6, page 5 line 12 and page 7 line 22 in the name of Lord Sharkey, replace the existing affirmative procedure with a super-affirmative procedure in order to increase parliamentary scrutiny.*



BARONESS FINLAY OF LLANDAFF  
LORD RIBEIRO

99 Page 9, line 28, leave out “may” and insert “must”

***Member’s explanatory statement***

*This amendment seeks to make the list of specified issues for the regulations to cover mandatory.*

100 Page 9, line 37, at end insert –

- “( ) requiring that, subject to patient consent, information about any medical device implanted in the human body is entered and retained in an information system established under subsection (1);
- ( ) requiring that, subject to patient consent, information about the use of other medical devices as may be necessary for the protection of patient safety is entered and retained in an information system established under subsection (1);
- ( ) requiring that information systems established under subsection (1) are subject to expert oversight;
- ( ) establishing a mechanism for patients to enter reports of their experience following the use of any medical device in their treatment, requiring that this information be retained in any relevant information system established under subsection (1).”

BARONESS FINLAY OF LLANDAFF  
BARONESS BENNETT OF MANOR CASTLE

101 Page 9, line 37, at end insert –

- “( ) establishing a mechanism for patients to enter reports of their experience following the use of any medical device in their treatment, to be retained in any relevant information system established under subsection (1).”

***Member’s explanatory statement***

*The amendment requires that patients should have a direct route to report their experience into any information system established under this section.*

BARONESS FINLAY OF LLANDAFF  
LORD RIBEIRO

102 Page 10, line 20, leave out “may” and insert “must”

***Member’s explanatory statement***

*This amendment seeks to strengthen the provisions of this Clause in relation to unique identifiers on medical devices, mandating, rather than permitting, their inclusion in the registration system set up by Clause 16.*

## BARONESS CUMBERLEGE

103 Page 10, line 41, at end insert –

- “( ) The Secretary of State must by regulations set out the categories or types of information held by the Information Centre or other persons that are subject to the consent of the patient to whom the information relates.”

**Member's explanatory statement**

*The purpose of this amendment is to clarify which information held by the healthcare system requires the consent of the patient to whom it relates.*

LORD LANSLEY  
LORD WOOLF  
BARONESS FINLAY OF LLANDAFF

104 Page 10, line 42, at end insert –

“( ) In making regulations under subsection (1), and in the use of information provided by virtue of this section, the Secretary of State must have regard to the Caldicott principles, as set out in the Report on the Review of Patient-Identifiable Information, published in 1997, and the Information Governance Review, published in 2013.”

**Member's explanatory statement**

*This amendment would require regulations under this section to have regard to the Caldicott principles.*

**After Clause 16**

BARONESS THORNTON  
BARONESS BENNETT OF MANOR CASTLE

105 Insert the following new Clause –

**“Requirement for consultation with devolved authorities**

- (1) Before making regulations under section 16 that contain provision which is within the legislative competence of a devolved legislature, the Secretary of State must consult the relevant devolved authority on that provision and have regard to the views of that devolved authority.
- (2) In this section –
  - “devolved authority” means the Scottish Ministers, the Welsh Ministers, Northern Ireland ministers or a Northern Ireland department; and
  - “devolved legislature” means the Scottish Parliament, Senedd Cymru or the Northern Ireland Assembly.
- (3) A provision is within the legislative competence of a devolved legislature if –
  - (a) it would be within the legislative competence of the Scottish Parliament if it were contained in an Act of the Scottish Parliament;
  - (b) it would be within the legislative competence of Senedd Cymru if it were contained in an Act of Senedd Cymru (including any provision that could only be made with the consent of a Minister of the Crown); or
  - (c) the provision, if it were contained in an Act of the Northern Ireland Assembly –
    - (i) would be within the legislative competence of the Assembly, and
    - (ii) would not require the consent of the Secretary of State.”

**Member's explanatory statement**

*This new Clause would require the Secretary of State to consult the devolved administrations before making regulations concerning UK-wide information systems.*

## BARONESS THORNTON

106 Insert the following new Clause—

**“Annual report on Medical Devices Information Systems**

- (1) The Secretary of State must, by the end of the period of 12 months beginning with the day on which this Act is passed, and every year thereafter, lay before Parliament a report on the operation of any information systems established by the Information Centre under the powers conferred by section 16 of this Act.
- (2) The annual report laid under subsection (1) must include, but is not limited to—
  - (a) the number of patients who receive or are treated with a medical device, or into whom a medical device is implanted;
  - (b) any safety concerns received; and
  - (c) any regulatory action taken.
- (3) The Secretary of State must provide a copy of every report laid before Parliament under this paragraph—
  - (a) to the Scottish Ministers,
  - (b) to the Welsh Ministers, and
  - (c) to the Northern Ireland Ministers or the relevant Northern Ireland department.”

***Member’s explanatory statement***

*This new Clause would require the Secretary of State to prepare a report about Medical Device registers operated by NHS Digital, lay it before Parliament and send it to the devolved administrations.*

BARONESS BARKER  
BARONESS BURT OF SOLIHULL

107 Insert the following new Clause—

**“Introduction of registries for patient safety**

- (1) Within 6 months of this Act coming into force, the Secretary of State must by regulations introduce provisions enabling the creation of a registry of patients who have undergone a procedure to insert surgical mesh.
- (2) The purpose of the registry under subsection (1) is to research and audit the outcomes of such surgeries in terms of the device safety and patient reported outcomes measures.
- (3) When creating the registry under subsection (1) the Government must consult—
  - (a) relevant patient groups;
  - (b) healthcare professionals; and
  - (c) anyone else whom the Secretary of State considers appropriate.
- (4) Accompanying the regulations the Secretary of State must also lay before Parliament a report outlining the progress towards the establishment of a comprehensive national database of patients who have undergone a procedure involving the insertion of a medical device or implant, and how the database may feed into the creation of further registries.

**After Clause 16 - continued**

- (5) A statutory instrument containing regulations under this section may not be made unless a draft of the instrument has been laid before and approved by a resolution of each House of Parliament.”

**Clause 35**

LORD PATEL  
LORD MACKAY OF CLASHFERN  
BARONESS CUMBERLEGE

108 Page 19, line 22, at end insert –

- “( ) The Secretary of State must disclose information for the purpose of warning the public about concerns relating to a medical device where there is a clear threat to public safety.”

***Member’s explanatory statement***

*This amendment places a duty on the Secretary of State to disclose the information where there is a clear threat to public safety.*

LORD BETHELL

109 Page 19, line 33, at end insert –

- “(4A) The Secretary of State may disclose information to a person outside the United Kingdom where required for the purpose of giving effect to an international agreement or arrangement concerning the regulation of medical devices.”

***Member’s explanatory statement***

*This amendment makes clear that information held by the Secretary of State in connection with medical devices can be disclosed, subject to certain restrictions, to persons outside the United Kingdom in order to give effect to a relevant international agreement or arrangement.*

110 Page 19, line 35, leave out “or (4)” and insert “, (4) or (4A)”

***Member’s explanatory statement***

*This amendment is consequential on amendment in the Minister’s name inserting a new subsection into Clause 35.*

111 Page 19, line 37, leave out “or (4)” and insert “, (4) or (4A)”

***Member’s explanatory statement***

*This amendment is consequential on the amendment in the Minister’s name inserting a new subsection into Clause 35.*

**Clause 37**

LORD FREYBERG  
LORD CLEMENT-JONES

112 Page 21, line 46, leave out “(7)” and insert “(8)”

**Clause 37 - continued**

**113** Page 22, line 2, at end insert—

“( ) In regulation 2 (interpretation), in paragraph (1) in the definition of “medical device”, after “software” insert “and algorithms including methodologies for the interpretation of data, and associated technical architecture,”.”

***Member’s explanatory statement***

*This amendment updates the definition of medical device to bring it in line with the EU and US regulation, acknowledging the progress of technology beyond the Medical Devices Regulations 2002.*

LORD PATEL  
LORD MACKAY OF CLASHFERN

**114** Page 22, line 3, leave out subsection (5)

***Member’s explanatory statement***

*This amendment means Regulation 3B remains in place.*

**After Clause 37**

LORD PATEL  
LORD KAKKAR

**115** Insert the following new Clause—

**“Requirement for consolidated legislation: medical devices**

The Secretary of State must publish draft legislation consolidating existing legislation as it applies to medical devices within three years after the day on which this Act is passed.”

***Member’s explanatory statement***

*This new Clause would commit the Secretary of State to introducing new, streamlined legislation within three years.*

BARONESS THORNTON

**116** Insert the following new Clause—

**“Requirement for draft consolidated legislation**

The Secretary of State must, within the period of two years beginning with the day on which this Act is passed, publish draft legislation consolidating the regulatory regime as it applies to medical devices.”

***Member’s explanatory statement***

*This new Clause would require the Secretary of State to publish draft consolidated legislation within two years to streamline the existing regulatory framework.*

**After Clause 38**

BARONESS CUMBERLEGE  
LORD PATEL  
LORD HUNT OF KINGS HEATH  
BARONESS JOLLY

117 Insert the following new Clause—

**“Independent Patient Safety Commissioner**

- (1) An independent Patient Safety Commissioner is established.
- (2) The Office of Patient Safety is to be hosted and funded by the Cabinet Office.
- (3) The Patient Safety Commissioner must publish a business plan, reviewed annually, which sets out, in relation to the discharge of the Commissioner’s functions—
  - (a) the Commissioner’s proposed main activities for the period covered by the plan (including the matters he or she intends to consider or investigate), and
  - (b) the Commissioner’s proposed strategic priorities for that period.
- (4) The Patient Safety Commissioner must appoint an advisory board to provide the Commissioner with advice and assistance relating to the discharge of his or her functions, consisting of persons who (taken together) represent a broad range of interests which are relevant to the Patient Safety Commissioner’s functions, and must from time to time publish a report on the procedure followed and the criteria used when making appointments to the advisory board.
- (5) The Commissioner’s functions are to—
  - (a) promote and improve patient safety with respect to the use of medicines and medical devices;
  - (b) promote the views and interests of patients and other members of the public in relation to the safety of medicines and medical devices;
  - (c) make recommendations to the Secretary of State;
  - (d) establish and, when deemed appropriate, revise Principles of Better Patient Safety;
  - (e) receive direct reports from patients and other members of the public, any other persons (whether natural or corporate), and the Secretary of State and, when the Commissioner deems appropriate, share those reports with relevant organisations and the Secretary of State;
  - (f) produce and lay before Parliament for the attention of any committees of either House whose remit covers medicines and medical devices—
    - (i) an Annual Report and Accounts, and
    - (ii) any other reports regarding patient safety, which may include recommendations to improve patient safety with respect to the use of medicines and medical devices.
- (6) For the purposes of subsection (5)(d), the Principles of Better Patient Safety must—
  - (a) describe expected patient safety outcomes relating to the safety of medicines and medical devices; and

**After Clause 38 - continued**

- (b) be drafted in consultation with the public.
- (7) For the purposes of subsection (5)(f), the Commissioner may require a public body and other persons (whether natural or corporate) to provide such information as is reasonable in order to fulfil that function relating to the safety of medicines and medical devices.
- (8) In fulfilling his or her functions, the Commissioner may do anything which appears to be necessary or expedient for the purpose of, or in connection with, the performance of his or her functions.
- (9) The Commissioner has the duty to involve and inform patients and other members of the public in carrying out his or her functions.
- (10) The Commissioner may make recommendations to the Minister for the Cabinet Office for any additional powers which the Commissioner considers may be necessary to fulfil the duties and functions under this section.
- (11) The Minister for the Cabinet Office may by regulations make any other provision relating to the establishment of the Commissioner, including—
- (a) the appointment of a Commissioner,
  - (b) the terms of office,
  - (c) remuneration and financial and other assistance,
  - (d) staff, and
  - (e) any other matters the Minister for the Cabinet Office considers appropriate.
- (12) A statutory instrument containing regulations under this section may not be made unless a draft of the instrument has been laid before and approved by a resolution of each House of Parliament.”

***Member’s explanatory statement***

*This new clause would establish the Patient Safety Commissioner on a statutory basis, as recommended in the report of the Independent Medicines and Medical Devices Safety Review.*

## BARONESS THORNTON

118

Insert the following new Clause—

**“International trade agreements**

- (1) Regulations under section 1(1), section 8(1) and section 12(1) may make provision for the purpose of implementing an international trade agreement, subject to the provisions of subsection (2).
- (2) No provision can be made for the purpose of implementing an international trade agreement if the provision would in any way undermine or restrict the ability of an appropriate authority—
- (a) to regulate and maintain the quality and safety of medicines and medical devices;
  - (b) to regulate and control the pricing and reimbursement systems for the purchase of medicines and medical devices; or
  - (c) to regulate and maintain the level of protection afforded in relation to information and patients’ data collected for the purpose of a register of medical devices.”

***Member's explanatory statement***

*This new Clause would protect medicines and medical devices regulations from any form of control from outside the UK in the event of a trade deal.*

BARONESS THORNTON  
BARONESS RITCHIE OF DOWNPATRICK

119 Insert the following new Clause –

**“Northern Ireland and regulatory divergence**

- (1) The Secretary of State must work together with the appropriate authority in Northern Ireland to minimise the potential for and mitigate against regulatory divergence in relation to human medicines, veterinary medicines and medical devices.
- (2) Where the Secretary of State has identified areas of regulatory divergence in relation to human medicines, veterinary medicines and medical devices between Northern Ireland and the rest of the UK, the Secretary of State must lay a report before both Houses of Parliament setting out how the divergence will impact –
  - (a) the UK; and
  - (b) Northern Ireland.
- (3) The report must set out the steps the appropriate authorities have taken to mitigate against such divergence.”

***Member's explanatory statement***

*This Clause would require the Secretary of State to work with the appropriate authority in Northern Ireland to minimise the potential for regulatory divergence relating to medicines and devices, and report any areas of regulatory divergence to Parliament, including the impact they will have, and report on actions to mitigate against adverse consequences arising from divergence.*

LORD PATEL  
LORD MACKAY OF CLASHFERN

120 Insert the following new Clause –

**“Northern Ireland and regulatory divergence**

- (1) The Secretary of State must make an annual report to Parliament on potential areas of regulatory divergence between Northern Ireland and the rest of the United Kingdom in matters covered by this Act.
- (2) Where the Secretary of State has identified areas of potential regulatory divergence between Northern Ireland and the rest of the United Kingdom, the Secretary of State must set out plans to mitigate the adverse effects of such divergence in the annual report.”

***Member's explanatory statement***

*This new Clause would require the Secretary of State to report on regulatory divergence between Northern Ireland and the rest of the UK.*



BARONESS CUMBERLEGE  
LORD HUNT OF KINGS HEATH  
BARONESS RITCHIE OF DOWNPATRICK

121 Insert the following new Clause—

**“Independent medicines and medical devices safety review: task force for implementation**

- (1) Within three months of this Act being passed, the Secretary of State must appoint an independent task force.
- (2) The task force must—
  - (a) have an independent Chair;
  - (b) be accountable to an oversight governance board; and
  - (c) include representatives of the Independent Medicines and Medical Devices Safety Review, published on 8 July 2020.
- (3) The task force’s functions are—
  - (a) to deliver a timeline for the implementation in full of the recommendations of the Review in subsection (2)(c); and
  - (b) to implement the recommendations of the Review in subsection (2)(c).
- (4) Once the task force has fulfilled the functions in subsection (3), it will cease to exist.”

*Member’s explanatory statement*

*This new clause would establish the task force whose role it would be to implement recommendations set out in the report of the Independent Medicines and Medical Devices Safety Review.*

LORD HUNT OF KINGS HEATH  
BARONESS CUMBERLEGE  
BARONESS BENNETT OF MANOR CASTLE

122 Insert the following new Clause—

**“Medicines and Medical Devices Redress Agency**

The Secretary of State must, by the end of the period of 12 months beginning with the day on which this Act is passed, bring proposals before Parliament to establish a Redress Agency for those harmed by medicines and medical devices.”

BARONESS CUMBERLEGE  
BARONESS BENNETT OF MANOR CASTLE

123 Insert the following new Clause—

**“Redress schemes**

The Secretary of State must, by the end of the period of three months beginning with the day on which this Act is passed, bring proposals before Parliament to establish redress schemes for those avoidably harmed by—

- (a) hormone pregnancy tests,
- (b) sodium valproate, and
- (c) pelvic mesh.”

**Member's explanatory statement**

*This new clause would require the Secretary of State to create redress schemes for those who have already suffered avoidable harm related to the medicines and medical devices specified in the new clause, and would thus implement one of the recommendations made in the report of the Independent Medicines and Medical Devices Safety Review.*

LORD HUNT OF KINGS HEATH

124 Insert the following new Clause –

**“Availability of medicines and medical devices for human use on the National Health Service**

- (1) The Secretary of State must require the National Institute for Health and Care Excellence to ensure that it takes account of the need for improved availability of innovative medicines and medical devices for human use on the National Health Service.
- (2) The Secretary of State must lay a report and impact assessment before both Houses of Parliament setting out how the implementation of the National Institute for Health and Care Excellence processes and methods programme manual will help to improve the availability of innovative medicines and medical devices for human use within the National Health Service.
- (3) The report in subsection (2) must set out the anticipated impact of the changes contained within the new programme manual on inward investment and the attractiveness of the UK life sciences sector for the development of medicines and medical devices.”

**Member's explanatory statement**

*This new Clause would require the Secretary of State to work with the National Institute for Health and Care Excellence to ensure that the latest medicines for human use are able to reach patients on the National Health Service.*

BARONESS JOLLY

125★ Insert the following new Clause –

**“Future regulatory alignment**

- (1) The appropriate authority must ensure that the provisions of regulations under section 1(1) and section 12(1) align as much as reasonably practicable with the relevant law of the European Union.
- (2) The Government must seek full membership of –
  - (a) the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use; and
  - (b) any other organisation the Government, in consultation with relevant industry bodies, believes will improve regulatory alignment with the European Union and standards in medicines and medical devices in the UK.”

**Member's explanatory statement**

*This new Clause is intended to probe the Government's intentions for future regulatory alignment with the European Union, and the UK's relationships with relevant international organisations following our exit from the European Union.*

**Clause 41**

LORD BETHELL

**126** Page 24, line 9, leave out “consult such persons as the authority considers appropriate” and insert “carry out a public consultation.

(1A) In relation to proposed regulations under section 16(1), the Secretary of State must specifically consult –

- (a) the Welsh Ministers,
- (b) the Scottish Ministers, and
- (c) the Department of Health in Northern Ireland.

(1B) In relation to proposed regulations under section 1(1), 8(1) or 12(1), the consultation document must include a summary of the relevant authority’s assessment of the matters mentioned in section 1(1A) and (2), 8(1A) and (2) or 12(1A) and (2)(as the case may be).”

***Member’s explanatory statement***

*This amendment requires a relevant authority to carry out a public consultation before making regulations under any provision of Part 1, 2 or 3, and to set out the authority’s assessment of any matter to which the authority must have regard in making the regulations, as well as requiring the Secretary of State to consult the devolved administrations in relation to regulations under clause 16(1).*

LORD PATEL

LORD MACKAY OF CLASHFERN

**127** Page 24, line 9, after “consult” insert “patients and end users directly affected by the regulations, and any other”

BARONESS THORNTON

LORD HUNT OF KINGS HEATH

**128** Page 24, line 9, leave out from “consult” to end and insert “–

- (a) healthcare organisations;
- (b) pharmaceutical organisations;
- (c) veterinary organisations;
- (d) medical research organisations;
- (e) patient representatives’ organisations; and
- (f) any other such persons the authority considers appropriate.”

***Member’s explanatory statement***

*This amendment strengthens the consultation provisions.*

LORD SHARKEY

BARONESS JOLLY

**129** Page 24, line 9, at end insert “which must include–

- (i) representatives of the relevant patient groups,
- (ii) medical research charities,
- (iii) the pharmaceutical industry,
- (iv) academic researchers;

**Clause 41 - continued**

- (b) publish on its website in advance of each consultation the—
- (i) terms, start date and length of that consultation,
  - (ii) proposed consultees, and
  - (iii) proposed date and method of the publication of its results.”

BARONESS THORNTON  
LORD HUNT OF KINGS HEATH

130 Page 24, line 19, leave out subsection (3)

***Member’s explanatory statement***

*This probing amendment removes the provision which enables the consultation requirements to have been satisfied by consultations that took place prior to the passing of this Act.*

**After Clause 41**

LORD BETHELL

131 Insert the following new Clause—

**“Reporting requirements**

- (1) As soon as reasonably practicable after the end of each reporting period, the Secretary of State must lay before Parliament a report on the operation of any regulations made by the Secretary of State under sections 1(1), 8(1) and 12(1) that were in force at any time during the reporting period.
- (2) In preparing a report, the Secretary of State must consult such persons as the Secretary of State considers appropriate.
- (3) A report must include a summary of—
  - (a) any concerns raised, or proposals for change made, by a person consulted in accordance with subsection (2), and
  - (b) the Secretary of State’s response to those concerns or proposals, including any plan the Secretary of State may have to make further regulations under section 1(1), 8(1) or 12(1).
- (4) The reporting periods are—
  - (a) the period of 24 months beginning with the day on which the first set of regulations under section 1(1), 8(1) or 12(1) comes into force, and
  - (b) each successive period of 24 months.”

***Member’s explanatory statement***

*This new Clause imposes reporting requirements on the Secretary of State in relation to the operation of regulations made under Clauses 1(1), 8(1) and 12(1).*

BARONESS THORNTON  
BARONESS BENNETT OF MANOR CASTLE

132 Insert the following new Clause –

**“Duty to consult devolved administrations**

- (1) Before making any regulations under this Act that contain provisions which are within the legislative competence of a devolved legislature, the Secretary of State must consult the Scottish Government, the Welsh Government and the Northern Ireland Executive as relevant, and have regard to their views.
- (2) In this section “devolved legislature” means the Scottish Parliament, Senedd Cymru or the Northern Ireland Assembly.
- (3) A provision is within the legislative competence of a devolved legislature if –
  - (a) it would be within the legislative competence of the Scottish Parliament if it were contained in an Act of the Scottish Parliament;
  - (b) it would be within the legislative competence of Senedd Cymru if it were contained in an Act of Senedd Cymru (including any provision that could only be made with the consent of a Minister of the Crown); or
  - (c) the provision, if it were contained in an Act of the Northern Ireland Assembly –
    - (i) would be within the legislative competence of the Assembly, and
    - (ii) would not require the consent of the Secretary of State.”

***Member’s explanatory statement***

*This new Clause requires the Government to consult the devolved administrations and have regard to their views before making regulations.*

**Clause 42**

LORD BETHELL

133 Page 24, line 36, leave out subsections (3) to (9) and insert –

- “(3) The procedure for making regulations under Part 1, 2 or 3 is to be determined in accordance with this table and subsection (4) –

**Clause 42 - continued**

<i>If the regulations contain provision made in reliance on</i>	<i>the regulations are subject to</i>
section 5(1)(a)	the negative procedure
section 10(1)(a)	the negative procedure
section 14(1)(a)	the negative procedure
paragraph 9 of Schedule 1	the negative procedure

section 6	(a) the made affirmative procedure, where the regulations contain a declaration that the person making them considers that they need to be made urgently to protect the public from an imminent risk of serious harm to health
	(b) the draft affirmative procedure in any other case
section 15	(a) the made affirmative procedure, where the regulations contain a declaration that the Secretary of State considers that they need to be made urgently to protect the public from an imminent risk of serious harm to health
	(b) the draft affirmative procedure in any other case
any other provision in Part 1, 2 or 3	the draft affirmative procedure

- (4) Provision that may be made by regulations subject to the negative procedure may be made by regulations subject to the draft affirmative procedure.
- (5) Where regulations are subject to “the negative procedure” –
- (a) in the case of regulations made by the Secretary of State acting alone, the statutory instrument containing the regulations is subject to annulment in pursuance of a resolution of either House of Parliament,
  - (b) in the case of regulations made by a Northern Ireland department acting alone, they are subject to negative resolution within the meaning given by section 41(6) of the Interpretation Act (Northern Ireland) 1954, and
  - (c) in the case of regulations made by the Secretary of State and a Northern Ireland department acting jointly, the statutory instrument containing the regulations is subject to –
    - (i) annulment in pursuance of a resolution of either House of Parliament, and
    - (ii) negative resolution within the meaning given by section 41(6) of the Interpretation Act (Northern Ireland) 1954.
- (6) Where regulations are subject to the “draft affirmative procedure” –
- (a) in the case of regulations made by the Secretary of State acting alone, the statutory instrument containing the regulations may not be made unless a draft of the instrument has been laid before and approved by a resolution of each House of Parliament,
  - (b) in the case of regulations made by a Northern Ireland department acting alone, they may not be made unless a draft of the regulations has been laid before and approved by a resolution of the Northern Ireland Assembly, and

**Clause 42 - continued**

- (c) in the case of regulations made by the Secretary of State and a Northern Ireland department acting jointly, the statutory instrument containing the regulations may not be made unless a draft of the instrument has been laid before and approved by a resolution of –
  - (i) each House of Parliament, and
  - (ii) the Northern Ireland Assembly.
- (7) Where regulations are subject to the “made affirmative procedure” –
  - (a) in the case of regulations made by the Secretary of State acting alone, the statutory instrument containing the regulations –
    - (i) must be laid before Parliament after being made, and
    - (ii) ceases to have effect at the end of the period of 40 days beginning with the day on which the instrument is made unless, during that period, the instrument is approved by a resolution of each House of Parliament,
  - (b) in the case of regulations made by the Department of Health in Northern Ireland acting alone, they –
    - (i) must be laid before the Northern Ireland Assembly after being made, and
    - (ii) cease to have effect at the end of the period of 40 days beginning with the day on which they are made unless, during that period, the regulations are approved by a resolution of the Assembly, and
  - (c) in the case of regulations made by the Secretary of State and the Department of Health in Northern Ireland acting jointly, the statutory instrument containing the regulations –
    - (i) must be laid before Parliament and the Northern Ireland Assembly after being made, and
    - (ii) ceases to have effect at the end of the period of 40 days beginning with the day on which the instrument is made unless, during that period, the instrument is approved by a resolution of each House of Parliament and by a resolution of the Assembly.
- (8) In calculating the period of 40 days for the purposes of subsection (7)(a)(ii) or (c)(ii) in relation to Parliament, no account is to be taken of any time during which –
  - (a) Parliament is dissolved or prorogued, or
  - (b) either House of Parliament is adjourned for more than 4 days.
- (9) In calculating the period of 40 days for the purposes of subsection (7)(b)(ii) or (c)(ii) in relation to the Northern Ireland Assembly, no account is to be taken of any time during which the Assembly is –
  - (a) dissolved,
  - (b) in recess for more than 4 days, or
  - (c) adjourned for more than 6 days.
- (10) If regulations cease to have effect as a result of subsection (7) that –
  - (a) does not affect the validity of anything previously done under the regulations, and
  - (b) does not prevent the making of new regulations.”

**Member's explanatory statement**

*This amendment provides for urgent regulations made in reliance on clauses 6 and 15 (emergencies) to be subject to the made affirmative procedure rather than the negative procedure and for regulations under clauses 2(1)(j), (k) or (n) and 9(1)(f), (k) or (l) to be subject to the draft affirmative procedure rather than the negative procedure.*

BARONESS THORNTON  
LORD HUNT OF KINGS HEATH

**134** Page 24, line 40, leave out subsections (4) to (9) and insert –

- “(4) Subject to subsection (11), regulations of a Northern Ireland department acting alone under section 1(1) or 8(1) may not be made unless a draft of the regulations has been laid before and approved by a resolution of the Northern Ireland Assembly.
- (5) Subject to subsection (15), a statutory instrument containing regulations of the Secretary of State and a Northern Ireland department acting jointly under section 1(1) or 8(1) may not be made unless a draft of the instrument has been laid before and approved by a resolution of –
  - (a) each House of Parliament, and
  - (b) the Northern Ireland Assembly.
- (6) A statutory instrument containing regulations of the Secretary of State acting alone to which subsection (16) applies may be made without a draft of the instrument being laid before, and approved by a resolution of, each House of Parliament.
- (7) A statutory instrument containing regulations made under subsection (6) must be laid before Parliament after being made.
- (8) Regulations contained in an instrument made in accordance with subsection (6) cease to have effect at the end of the period of 28 days beginning with the day on which the instrument is made unless, during that period, the instrument is approved by a resolution of each House of Parliament.
- (9) In calculating the period of 28 days for the purpose of subsection (8), no account is to be taken of any time during which –
  - (a) Parliament is dissolved or prorogued, or
  - (b) either House of Parliament is adjourned for more than four days.
- (10) Where regulations cease to have effect as a result of subsection (8), that does not –
  - (a) affect the validity of anything previously done under the regulations, or
  - (b) prevent the making of new regulations.
- (11) Regulations of a Northern Ireland department acting alone to which subsection (16) applies are subject to the made affirmative procedure.
- (12) For the purposes of subsection (11), “subject to the made affirmative procedure” means that the regulations –
  - (a) must be laid before the Northern Ireland Assembly as soon as reasonably practicable after being made, and
  - (b) cease to have effect at the end of the period of 40 days beginning with the day on which the regulations are made, unless during that period the regulations are approved by a resolution of the Northern Ireland Assembly.



**Clause 42 - continued**

- (13) In calculating the period of 40 days mentioned in subsection (12)(b), no account is to be taken of any time during which the Northern Ireland Assembly is –
- (a) dissolved,
  - (b) in recess for more than four days, or
  - (c) adjourned for more than six days.
- (14) Where by virtue of this section a Northern Ireland department makes regulations that are subject to the made affirmative procedure and the regulations cease to have effect because they are not approved within the period mentioned in subsection (12)(b), the fact that the regulations cease to have effect does not –
- (a) affect anything previously done under or by virtue of the regulations, or
  - (b) prevent the making of new regulations.
- (15) A statutory instrument containing regulations of the Secretary of State and a Northern Ireland department acting jointly to which subsection (16) applies is subject to –
- (a) the made affirmative procedure in Parliament (as described in subsections (6) to (10)), and
  - (b) the made affirmative procedure in the Northern Ireland Assembly (as described in subsections (12) to (14)).
- (16) This subsection applies to regulations that contain only provision made in reliance on –
- (a) section 6, where the regulations contain a declaration that the person making them considers that they need to be made urgently to protect the public from an imminent risk of serious harm to health; or
  - (b) section 15, where the regulations contain a declaration that the Secretary of State considers that they need to be made urgently to protect the public from an imminent risk of serious harm to health.”

***Member’s explanatory statement***

*This amendment removes provision for certain regulations to be subject to the negative procedure and would thus require all regulations to be subject to the affirmative procedure. In declared urgent cases, regulations would be subject to the made affirmative procedure, rather than the negative procedure as the Bill currently allows for.*

LORD SHARKEY  
LORD FORSYTH OF DRUMLEAN  
BARONESS ANDREWS

135 Page 25, line 8, leave out from “to” to “if” in line 9 and insert “the made affirmative procedure”

LORD SHARKEY

136 Page 25, line 12, leave out from beginning to “if” in line 13 and insert “the confirmatory procedure under the Statutory Rules (Northern Ireland) Order 1979”

**Clause 42 - continued**

LORD PATEL  
LORD PANNICK  
LORD MACKAY OF CLASHFERN

137 Page 25, line 27, leave out sub-paragraph (iii)

***Member's explanatory statement***

*This amendment will require that regulations under Clause 6 are subject to the affirmative resolution procedure.*

138 Page 25, line 34, leave out sub-paragraph (vii)

***Member's explanatory statement***

*This amendment will require that regulations under Clause 15 are subject to the affirmative resolution procedure.*

**After Clause 42**

LORD SHARKEY  
BARONESS JOLLY

139 Insert the following new Clause—

**“Expiry of powers**

All the powers to make regulations contained in this Act expire at the end of the period of three years beginning with the day on which this Act is passed.”

BARONESS THORNTON  
LORD HUNT OF KINGS HEATH

140 Insert the following new Clause—

**“Time limits on delegated powers**

Sections 1, 8, 12 and 16 of this Act, and the powers they confer, expire at the end of the period of two years beginning with the day on which they come into force.”

***Member's explanatory statement***

*This new Clause would ensure that the delegated powers are time limited to 2 years.*

LORD PATEL  
LORD PANNICK  
LORD MACKAY OF CLASHFERN

141 Insert the following new Clause—

**“Expiry of powers**

Sections 1, 8, and 12 and the powers conferred under those sections expire at the end of the period of three years beginning with the day on which this Act is passed.”

***Member's explanatory statement***

*This amendment is a sunset Clause on sections 1, 8 and 12 of the Bill.*

LORD SHARKEY  
LORD FORSYTH OF DRUMLEAN  
BARONESS ANDREWS

142 Insert the following new Clause—

**“Made affirmative procedure**

A statutory instrument containing regulations subject to the made affirmative procedure must be laid before Parliament as soon as reasonably practicable after being made and ceases to have effect at the end of the period of 40 days beginning with the day on which the instrument is made, unless during that period the instrument is approved by a resolution of each House of Parliament.”

143 Insert the following new Clause—

**“Super-affirmative procedure**

- (1) For the purposes of section 1(1), section 8(1), section 12(1) and section 16(1), the “super-affirmative procedure” is as follows.
- (2) The Secretary of State must lay before Parliament—
  - (a) a draft of the regulations, and
  - (b) a document which explains the draft regulations.
- (3) Where a draft of the regulations is laid before Parliament under subsection (2), no statutory instrument containing the regulations is to be laid before Parliament until after the expiry of the 30-day period.
- (4) The Secretary of State must request a committee of either House whose remit includes health, science or technology to report on the draft regulations within the 30-day period.
- (5) In preparing a draft statutory instrument containing the regulations, the Secretary of State must take account of—
  - (a) any representations,
  - (b) any resolution of either House of Parliament, and
  - (c) any recommendations of a committee under subsection (4),made within the 30-day period with regard to the draft regulations.
- (6) If, after the 30-day period, the Secretary of State wishes to make regulations in the terms of the draft or a revised draft, he or she must lay before Parliament a statement—
  - (a) stating whether any representations, resolutions or recommendations were made under subsection (5);
  - (b) giving details of any representations, resolutions or recommendations so made; and
  - (c) explaining any changes made in any revised draft of the regulations.
- (7) The Secretary of State may make a statutory instrument containing the regulations (whether or not revised) if, after the laying of the statement required under subsection (6), a draft of the instrument has been laid before and approved by a resolution of each House of Parliament.

**After Clause 42 - continued**

- (8) In this section, reference to “the 30-day period” in relation to any draft regulations is to the period of 30 days beginning with the day on which the original draft regulations were laid before Parliament.
- (9) For the purposes of subsection (8) no account is to be taken of any time during which Parliament is dissolved or prorogued or during which either House is adjourned for more than four days.”

**144** Insert the following new Clause –

**“Super-affirmative procedure: Northern Ireland**

- (1) For the purposes of section 1(1), section 8(1), section 12(1) and section 16(1), the “super-affirmative resolution procedure” in the Northern Ireland Assembly is as follows.
- (2) The Department must request a committee of the Assembly whose remit includes health, science or technology to report on the draft order within the 30-day period.
- (3) A Northern Ireland Department must take account of –
  - (a) any representations,
  - (b) any resolution of the Assembly, and
  - (c) any recommendations of a committee under subsection (2),
 made within the 30-day period.
- (4) If, after the 30-day period, the Department wishes to make an order in the terms of the draft, it must lay before the Assembly a statement –
  - (a) stating whether any representations were made under subsection (2)(a); and
  - (b) if any representations were so made, giving details of them.
- (5) The Department may after the laying of such a statement lay before the Assembly for approval by affirmative resolution the draft order in its initial form, or a revised draft order together with an explanation of the changes made.
- (6) In this section, reference to the “30-day period” in relation to any draft order is to the period of 30 days beginning with the day on which the original draft order was laid before the Assembly.
- (7) For the purposes of subsection (6) no account is to be taken of any time during which the Assembly is dissolved or adjourned for more than four days.”

**Clause 44**

LORD SHARKEY  
BARONESS JOLLY

**145** Leave out Clause 44 and insert the following new Clause –

**“Commencement**

This Act comes into force on the day on which it is passed.”

**Schedule 1**

BARONESS THORNTON  
LORD HUNT OF KINGS HEATH

**146** Page 34, line 10, leave out “have regard to” and insert “act in accordance with”

***Member’s explanatory statement***

*This amendment places a duty on the Secretary of State to follow, rather than have regard to, guidance.*

# Medicines and Medical Devices Bill

---

MARSHALLED  
LIST OF AMENDMENTS  
TO BE MOVED  
IN GRAND COMMITTEE

---

*14 October 2020*

---